Results 141 to 150 of about 33,626 (284)

Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Keita Kakuda, Yasuyoshi Kimura, Lindun Ge, Kensuke Ikenaka, Kanako Asai, Shunpei Murakami, Kotaro Ogawa, Hideki Mochizuki   +7 more
wiley   +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M. Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N.H. Nudelman, Andrew Siderowf, Caroline M. Tanner, Thomas F. Tropea, Tatiana Foroud, Lana M. Chahine, Brit Mollenhauer, Kalpana M. Merchant, Douglas Galasko, Christopher S. Coffey, Roseanne D. Dobkin, Ethan G. Brown, Roy N. Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez‐Latapi, Nicola Pavese, Kathleen L. Poston, the Parkinson's Progression Markers Initiative   +30 more
wiley   +1 more source

Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 (MxMD‐ADCY5)

Movement Disorders, EarlyView.
Abstract Background Mixed movement disorders linked to ADCY5 (MxMD‐ADCY5) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5. Psychiatric symptoms are suspected to be part of the phenotype. Objective The study aim was to assess psychiatric comorbidities in patients with MxMD‐ADCY5.
Aurélie Méneret, Clément Tarrano, Asya Ekmen, Diane Doummar, Victoria Gonzalez, Christine Tranchant, Mathieu Anheim, Philippe Damier, Eoin Mulroy, Kailash P. Bhatia, Laura Cif, Carlo Fusco, Miryam Carecchio, Norbert Brüggemann, Alexander Münchau, Florence Riant, Manon Gomes, Vanessa Brochard, Agathe Roubertie, Oriane Trouillard, Caroline Dubacq, Yulia Worbe, Mohamed Doulazmi, Emmanuel Roze   +23 more
wiley   +1 more source

Lingual Dyskinesia Developing after the First Dose of Methylphenidate Treatment in a Child with Neurodevelopmental Disorders: Genetic Predispositions. [PDF]

Clin Psychopharmacol Neurosci
Karagöz D, Kurt HİZ, Şahin N.
europepmc   +1 more source

The clinical effects of chlorpromazine on dyskinesia.

, 1954
W F T Tatlow, Clemency Fisher, Allen B. Dobkin   +2 more
openalex   +1 more source

Combined Use of EMG and Muscle Ultrasound for the Evaluation of Scapular Winging

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Scapular winging occurs as an abnormal protrusion of the scapula due to nerve injury, muscle weakness, bone, or joint pathology. The main muscular stabilizers of the scapula include the serratus anterior, trapezius, rhomboid major and minor, levator scapulae, and pectoralis minor.
Benjamin P. Rardin, James B. Meiling, Michael S. Cartwright, James B. Caress   +3 more
wiley   +1 more source

Chorea After MR-Guided Focused Ultrasound Thalamotomy. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Hooshmand SJ, Liu T, Ali R, Kaufmann T, Lehman V, Klassen B, Jackson L.   +6 more
europepmc   +1 more source

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment [PDF]

, 2004
Enrico Lattuada, Roberto Cavallaro, Alessandro Serretti, Cristina Lorenzi, Enrico Smeraldi   +4 more
openalex   +1 more source

rs6971 TSPO polymorphism in Parkinson's disease

Movement Disorders, EarlyView.
Bina Patel, Marta Camacho, Jonathan R. Evans, David P. Breen, Thomas Foltynie, Sarah L. Mason, Gemma Cummins, Ruwani Wijeyekoon, Roger A. Barker, Caroline Helen Williams‐Gray   +9 more
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source